Arvinas, Inc

ARVNNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
7.31 USD
↘ 0.15 (2.01%)AT CLOSE (03:59 PM EDT)
7.32
↗ 0.01 (0.07%)
POST MARKET (AS OF 07:57 PM EDT)
Post Market
AS OF 07:57 PM EDT
7.32
↗ 0.01 (0.07%)
🔴Market: CLOSED

Shares of Arvinas, Inc (ARVN) are trading at $7.32. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". This is driven by a concerning Altman Z-Score in the distress zone, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest ARVN is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Oct 6, 2026.

Open?$7.49
High?$7.49
Low?$7.28
Prev. Close?$7.46
Volume?585.8K
Avg. Volume?783.0K
VWAP?$7.36
Rel. Volume?0.75x
Bid / Ask
Bid?$6.30 × 100
Ask?$8.35 × 100
Spread?$2.05
Midpoint?$7.32
Valuation & Ratios
Market Cap?487.8M
Shares Out?64.5M
Float?54.6M
Float %?84.7%
P/E Ratio?52.45
P/B Ratio?0.87
EPS?$0.14
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
246
Market Cap
487.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.arvinas.com
Listed
2018-09-27
Address
395 WINCHESTER AVE
NEW HAVEN, CT 06511
Phone: 203-535-1456
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
9
Momentum?
85
Short Sent.?
35
Piotroski F-Score?6/9Mixed
Altman Z-Score?0.87Distress
Confidence?53%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?9.13%Elevated
Short Interest?5.0M
Days to Cover?5.6
Free Float54.6M
Avg Daily Volume891.6K
Settlement Date2026-09-15
Financial Health
Current Ratio?7.91Strong
Quick Ratio?7.91Strong
Cash Ratio?1.14Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
87/100
P/E?
Peers
100
S&P
11
52.5PRICEY▾
P/B?
Peers
100
S&P
97
0.87CHEAP▾
P/S?
Peers
100
S&P
78
1.54CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-36.1CHEAP▾
EV/Sales?
Peers
100
S&P
88
1.24CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
17
1.7%WEAK▾
ROA?
Peers
50
S&P
15
1.4%WEAK▾
Cash Flow & Enterprise
FCF?$-208800000
Enterprise Value?$393.8M
Fundamentals ratios updated end of day
MarketsMoversWatchlist